LEUKOCARE grants license to US vaccine company PaxVax
LEUKOCARE AG, Germany, and PaxVax, Inc., USA, today announced that both partners have entered into a licensing agreement granting PaxVax access to LEUKOCARE’s proprietary SPS® formulation technology platform for the clinical development and subsequent commercialization of one of PaxVax’s live viral vaccine products.
- 13.09.2016, 10:46
- Kategoria: Zdrowie i styl życia
- Źródło: APA-OTS